Loading…

Ceribell, Inc.CBLLCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum leader 83
Mkt cap
$995M
US dollars, full cap
Free float
67%
of shares outstanding
$/day
$15.6M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 9.3%
Hurdle
n/a
no reverse DCF
Next earnings
104 days
2 Mar 2027
Close · USD$25.63
1D-1.3%
1W-7.8%
1M-7.4%
3M+5.4%
6M+41.6%
YTD+16.9%
1Y+98.8%
ATR %5.4%
Beta1.15
52w lowhigh11.3% off high

What Ceribell does

Employees: 327

Ceribell at a glance

Size Ceribell (CBLL) is a United States Health Care company (Medical Specialties) with a market value of $995M, the 2236th largest of 3,085 United States companies the cockpit tracks. Shares closed at $25.63 on 18 Nov 2026.

Performance Over six months the shares gained 41.6%, against -7.9% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 20 in its peer set.

Growth Revenue grew 31.3% over the last twelve months (peer median +10.2%); the operating margin is -69.8% (peer median 11.7%).

Valuation It trades at 8.3× enterprise value to sales against a peer median of 3.5× (5th most expensive of 21).

Short interest Short interest is 5.0% of the free float (30 Oct 2026).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026CBLL 137Peer median 92
Six months, rebased to 100: Ceribell against the median of its 20 peers (local-currency closes).

Ceribell financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$109M$89.1M$65.4M$45.2M$25.9M
Revenue growth—+36%+45%+74%—
Gross profit$97.0M$78.3M$56.8M$38.2M$21.5M
EBITDA-$74.8M-$57.1M-$38.6M-$29.2M-$35.5M
Net income-$73.9M-$53.4M-$40.5M-$29.5M-$37.2M
Free cash flow-$56.4M-$41.7M-$36.7M-$30.1M-$32.5M
Capital expenditure$2.36M$1.52M$1.60M$1.76M$1.40M
Total debt$21.6M$22.3M$22.0M$14.2M$18.2M

Quarterly statements and history in the cockpit →

Ceribell competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%+20%30020630014330068565233010216000557730EUZCSTL3046SFL7780290650IRMDSIBN688622301101214150CBLL6-month return →1-month return →
Up and to the right = strong over both horizons. Ceribell is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%0×25×50×75×3002063001433006856523301021600055290650688622301101IARTCBLLRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ceribell is the large dot.

Ceribell competitors and peer comparison

How Ceribell compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ceribell against its 20 peers (data as of 18 Nov 2026)
MeasureCBLLPeer medianRank in peer set
1-month return-7.4%-1.9%6th lowest of 21
6-month return+41.6%-7.9%4th highest of 20
Distance from 52-week high-11.3%-28.9%5th highest of 21
Revenue growth (TTM)+31.3%+10.2%2nd highest of 20
Operating margin-69.8%11.7%2nd lowest of 21
EV / Sales8.3×3.5×5th most expensive of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Ceribell CBLLUnited States$995M+42%+31%-70%8.3×n/an/a
Edan Instruments 300206.SZChina$1.00B-19%+14%17%2.5×6.9%-2.9%
INKON Life Technology 300143.SZChina$985M-23%+22%12%3.1×10.7%+12.9%
Amoy Diagnostics 300685.SZChina$1.01B-15%+7%34%4.7×4.9%+10.4%
PHC 6523.TJapan$1.02B+34%+3%8%0.9×-4.0%+3.5%
Inno Laser Technology 301021.SZChina$1.03B-33%+17%9%11.1×50.8%+8.6%
Beijing Wandong Medical Technology 600055.SSChina$1.03B-26%-11%-33%3.0×n/an/a
Mani 7730.TJapan$965M-7%+10%30%3.9×3.3%+13.9%
Eckert & Ziegler EUZ.DEGermany$1.03B-2%+4%26%2.7×7.7%+12.1%
Castle Biosciences CSTLUnited States$1.03B+67%+10%-7%2.1×57.7%+40.6%
JINS 3046.TJapan$963M-8%+14%10%1.3×-6.1%+11.7%
Safilo SFL.MIItaly$953M+42%-4%9%0.9×1.3%+4.7%
Menicon 7780.TJapan$944M+26%+6%9%1.5×n/an/a
L&C BIO 290650.KSSouth Korea$943M-37%+65%20%9.7×32.6%+21.0%
IRadimed IRMDUnited States$1.05B-9%+11%32%11.1×18.5%+21.5%
SI-BONE SIBNUnited States$1.06B+59%+14%-8%4.3×n/an/a
Guangzhou Hexin Instrument 688622.SSChina$1.06B+21%-29%-74%85.0×n/an/a
Mingyue Optical Lens 301101.SZChina$1.07B-4%+14%25%6.3×8.8%+8.8%
Integra LifeSciences IARTUnited States$1.08B-10%+1%12%1.7×5.9%+3.6%
CLASSYS 214150.KSSouth Korea$1.08B-60%+16%43%4.0×-9.2%+34.5%
Freenome FRNMUnited States$1.08Bn/an/a36%4.7×n/an/a

Questions

Which companies are Ceribell's closest peers?
The cockpit's peer set: Edan Instruments (300206.SZ), INKON Life Technology (300143.SZ), Amoy Diagnostics (300685.SZ), PHC (6523.T), Inno Laser Technology (301021.SZ), Beijing Wandong Medical Technology (600055.SS), Mani (7730.T), Eckert & Ziegler (EUZ.DE).
Is Ceribell expensive compared with its peers?
On ev / sales it trades at 8.3× against a peer median of 3.5×, 5th most expensive of 21 in its peer set.
How has Ceribell stock performed?
Over six months to 18 Nov 2026 the shares returned +41.6% against -7.9% for the median peer; over one year +98.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.